We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,599.50
Ask: 1,600.00
Change: 15.50 (0.98%)
Spread: 0.50 (0.031%)
Open: 1,579.50
High: 1,600.00
Low: 1,575.00
Prev. Close: 1,583.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

22 Apr 2014 07:46

GlaxoSmithKline says Novartis deal could lead to more disposals

LONDON, April 22 (Reuters) - GlaxoSmithKline said the group's deal with Novartis narrowed its focus on the key areas of vaccines, respiratory, consumer and HIV medicines, and could be followed by the disposal of its portfolio of older drugs. Chief Executive Andrew Witty said the core areas

Read more
22 Apr 2014 07:39

UK MORNING BRIEFING: Glaxo And AstraZeneca Put M&A In Focus

LONDON (Alliance News) - UK shares have opened slightly higher Tuesday following gains on Wall Street over the long Easter weekend.

Merger and acquisition activity and discussion surrounding UK pharmaceutical giants GlaxoSmithKline and AstraZeneca

Read more
22 Apr 2014 07:29

BUZZ-Healthcare M&A: what the doctor ordered

A spate of deal headlines in the European pharma sector is putting a floor under regional stock indices. ** Busy Easter for dealmakers with Novartis and GlaxoSmithKline leading the charge. ** Pfizer could get back into mega-deal mode after a 4-year hiatus. A reported 60 billion pound

Read more
22 Apr 2014 07:04

Glaxo announces massive three-part deal with Swiss peer Novartis - UPDATE

- GSK to return 4bn pounds to shareholders after Novartis three-part deal - Companies to create new consumer business - Novartis to sell Vaccines business to GSK - GSK to sell Oncology portfolio to Novartis - Means 10bn dollar surplus payment to GSK GlaxoSmithKline (GSK) has announced a major three

Read more
22 Apr 2014 06:52

UPDATE: GlaxoSmithKline Inks Deal With Novartis To Sell Oncology Portfolio, Acquire Vaccines Business

LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday it has signed a three-part inter-conditional transaction with Novartis AG which will see it sell off its Oncology portfolio, acquire Novartis' global Vaccines business, and create a dually-offered Consumer Healthcare business. The tr

Read more
22 Apr 2014 06:41

MARKET COMMENT: UK Stocks To Open Slightly Higher With M&A In Focus

LONDON (Alliance News) - UK stocks are set to open marginally higher Tuesday, as European markets play catch-up with Wall Street, which made gains over the long Easter weekend despite ongoing tensions in Ukraine. Spreadbetters are indicating that the FTSE 100 will open slightly higher Tuesd

Read more
22 Apr 2014 06:33

DIRECTOR DEALINGS: Glaxo Executives Acquire Shares, ADSs

LONDON (Alliance News) - GlaxoSmithKline PLC Thursday said a group of executives including Chief Executive Officer Andrew Witty acquired shares and American Depositary Shares under the company performance share plan at a price of 1581.50 pence per share and USD52.55 per ADS Wednesday.
Read more

22 Apr 2014 06:12

CORRECTED-Novartis exchanges assets with Glaxosmithkline

(Corrects $7.1 million to $7.1 billion in second paragraph) ZURICH, April 22 (Reuters) - Swiss drugmaker Novartis said on Tuesday it would exchange certain assets with GlaxoSmithKline and divest its animal health business to Eli Lilly. Novartis said it had agreed to acquire GSK's onc

Read more
22 Apr 2014 06:00

GlaxoSmithKline To Create Consumer Healthcare Business With Novartis, To Sell And Acquire Units

LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday it has signed a three-part inter-conditional transaction with Novartis AG which will see it sell off its Oncology portfolio, acquire Novartis' global Vaccines business, and create a dually-offered Consumer Healthcare business. The tr

Read more
21 Apr 2014 21:51

UPDATE 3-AstraZeneca cancer pipeline seen as draw for Pfizer

(Adds Breakingviews link) By Ben Hirschler LONDON, April 21 (Reuters) - Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal could make sense for the U.S. pharmaceutica

Read more
21 Apr 2014 14:00

MARKET PULSE-AMD, Cbeyond, Halliburton, Plug Power, Prosensa, Sarepta

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) April 21 (Reuters) - U.S. stocks opened flat on Monday as investors found few reasons to

Read more
21 Apr 2014 13:58

CORRECTED-MARKET PULSE-AMD, Halliburton, Hasbro, Prosensa, Sarepta, Shanda

(Corrects Calpine's ticker symbol and its Thursday closing price. Removes reference to stock's price decline due to the same error) April 21 (Reuters) - U.S. stock index futures pointed to a flat open on Monday as investors found few reasons to keep buying following a strong rally last w

Read more
21 Apr 2014 13:55

CORRECTED-MARKET PULSE-AMD, Halliburton, Hasbro, Newmont, Prosensa, Sarepta

(Corrects Calpine's ticker symbol and its Thursday closing price) April 21 (Reuters) - U.S. stock index futures were very slightly higher on Monday. Dow Jones industrial average futures were up 0.06 percent at 16,352, S&P 500 futures were up 0.04 percent at 1,858.7 and Nasdaq 100 futures

Read more
21 Apr 2014 11:43

MARKET PULSE-Apple, GM, Google, Halliburton, Hasbro, Pfizer, Sprint

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) April 21 - ** HALLIBURTON CO, Thursday close $60.9 The oilfield services company

Read more
20 Apr 2014 14:00

UPDATE 1-Pfizer considers $100 bln bid for AstraZeneca - report

(Adds no comment from Pfizer and AstraZeneca, context) LONDON, April 20 (Reuters) - U.S. pharmaceutical giant Pfizer has approached British rival AstraZeneca to propose a 60 billion pound ($101 billion) takeover, Britain's Sunday Times reported. The paper cited senior investment bank

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.